Day 1: Tuesday, Sept. 29, 2026
2–5:30 p.m. ET
Tinkham Veale University Center
| 2-2:05 p.m. | INTRODUCTION |
| 2:05–2:25 p.m. | YEAR OF ACCOMPLISHMENTS Gary Schwartz, MD Director, Case CCC |
| 2:30 p.m. | TED TALK SESSIONS |
| 2:30–2:50 p.m. | Waverly Willis |
| 2:50–3:10 p.m. | Gregory Hall, MD Founder & Board Chairman, National Institute for African American Health, Medical Director, Cutler Center for Men – University Hospitals of Cleveland |
| 3:10–3:30 p.m. | Honey Bell Bey Cuyahoga County Poet Laureate, Poet/Activist and Founder of The Distinguished Gentleman of the Spoken Word |
| 3:30–3:40 p.m. | POSTER TRANSITION |
| 3:40-5:30 | POSTER SESSION AND RECEPTION |
Day 2: Wednesday, Sept. 30, 2025
7:30 a.m.–5:00 p.m. ET
Tinkham Veale University Center
| 7:30 a.m. | BREAKFAST |
| 8–8:10 a.m. | WELCOME REMARKS Rebecca Obeng, MD, PhD and Monica Wagner, PhD, RN |
| 8:10–8:30 a.m. | INTRODUCTION, VISION, AND STRATEGIC DIRECTIONS Gary Schwartz, MD Director, Case CCC |
| 8:30–8:45 a.m. | SESSION I: Tumor Host Interactions MODERATORS: Daniel McGrail, PhD and Kristen VanHeyst, DO |
| 8:45–9:05 a.m. | Li Lilly Wang, PhD Member, Immune Oncology Program Cleveland Clinic |
| 9:05–9:25 a.m. | Chris Hubert, PhD Member, Molecular Oncology Program Case Western Reserve University |
| 9:25–9:45 a.m. | Evi Stavrou, MD Member, Molecular Oncology Program Case Western Reserve University |
| 9:45–9:55 a.m. | HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy Chao Wei, PhD Postdoctoral Scholar Wang Lab Case Western Reserve University |
| 9:55–10:05 a.m. | PANEL DISCUSSION/QUESTIONS |
| 10:05–10:20 a.m. | BREAK |
| 10:20–10:25 a.m. | SESSION II: Novel Therapeutics MODERATORS: Melissa Lumish, MD and Drew Adams, PhD |
| 10:25–10:45 a.m. | Agata Exner, PhD Program Leader, Cander Imaging Program Case Western Reserve University |
| 10:45–11:05 a.m. | Shawn Stauffer, PhD Member, Developmental Therapeutics Program Cleveland Clinic |
| 11:05–11:25 a.m. | Rui Wang, PhD Member, Molecular Oncology Case Western Reserve University |
| 11:25–11:35 a.m. | Structure-Guided Development of Selective SLC1A1/EAAT3 Inhibitors Targeting Renal Cancer Metabolism Pooneh Koochaki, MD Postdoctoral Research Fellow Chakraborty Lab Cleveland Clinic |
| 11:35–11:45 a.m. | PANEL DISCUSSION/QUESTIONS |
| 11:45 a.m.–1 p.m. | LUNCH/PROGRAM BREAKOUT ROOMS
|
| 1-1:15 p.m. | BREAK |
| 1:15–1:20 p.m. | INTRODUCTION TO KEYNOTE ADDRESS |
| 1:20–2:20 p.m. | KEYNOTE ADDRESS Deciphering and targeting clonal evolution Ross Levine, MD Chief Scientific Officer, Memorial Sloan Kettering Cancer Center |
| 2:20–2:30 p.m. | BREAK |
| 2:30–2:35 p.m. | SESSION III: Genetics and Clinical Outcomes MODERATOR: Jacob Miller, MD and Madelyn Stevens, MD |
| 2:35–2:55 p.m. | Richa Sharma, MD Member, Cancer Genomics and Epigenetics Program Cleveland Clinic |
| 2:55–3:15 p.m. | Jonathan Shoag, MD Member, Population and Cancer Prevention Program Case Western Reserve University |
| 3:15–3:35 p.m. | Seth Rotz, MD Member, Population and Cancer Prevention Program Cleveland Clinic |
| 3:35–3:45 p.m. | Radiation-Induced HER2 Upregulation Sensitizes HER2-Low Breast Cancer Brain Metastases to Trastuzumab Deruxtecan Qing Li, MD, PhD Resident Miller Lab University Hospitals |
| 3:45–3:55 p.m. | PANEL DISCUSSION/QUESTIONS |
| 3:55–4:10 p.m. | POSTER AWARDS CONCLUDING REMARKS |
| 4:10–4:30 p.m. | PROGRAM LEADERS/EXECUTIVE COMMITTEE (CLOSED SESSION) |